Quantcast

NYC Gazette

Friday, February 21, 2025

Memorial Sloan Kettering partners with AWS for AI-driven cancer research

Webp 6k40a9sl0oemwfverp6i17soyxof

Carol Brown Senior Vice President and Chief Health Equity Officer | Memorial Sloan Kettering Cancer Center

Carol Brown Senior Vice President and Chief Health Equity Officer | Memorial Sloan Kettering Cancer Center

Amazon Web Services (AWS) and Memorial Sloan Kettering Cancer Center (MSK) have announced a partnership to advance cancer research through artificial intelligence (AI), high-performance computing, and cloud technology. The collaboration aims to address the growing global health challenge of cancer, with projected deaths reaching 15 million annually by 2040.

AWS will provide MSK with advanced tools and technology to analyze clinical research and treatment data. This initiative will involve deidentified genomic, imaging, and clinical data to support AI-driven cancer research and personalized treatment development. The goal is to create a comprehensive data resource for ongoing cancer research at MSK.

"MSK’s collaboration with AWS is rooted in our shared vision and commitment to accelerate the pace with which we ideate, create, and bring lifesaving innovations to cancer patients," said Dr. Anaeze Offodile II, MSK Chief Strategy Officer.

The use of large language models through Amazon Bedrock and Amazon SageMaker will enhance data quality for AI model building. This approach allows MSK researchers to track patient disease trajectories over time, potentially leading to personalized treatments and improved patient care.

Dave Levy, AWS Vice President of Worldwide Public Sector and Healthcare and Life Sciences, stated: "Pairing MSK’s cancer research expertise...with AWS’s advanced cloud and AI capabilities creates a powerful engine for innovation."

The collaboration also includes plans to expand MSK's Innovation Hub for digital solutions in oncology challenges. AWS will support technology pilots within this hub by providing funding and access to its AI expertise. A new entrepreneurship program for oncology innovators will also receive backing from AWS.

In drug discovery efforts, the partnership will utilize AWS resources like the Drug Discovery Workbench and ParallelCluster to accelerate therapeutic discoveries for cancers with high unmet needs. This aims to streamline drug development processes significantly.

Contact:

Annik Allen

Manager, Media Relations

[email protected]

MORE NEWS